The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca/Hong Kong; Bayer; Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Roche
Consulting or Advisory Role - AstraZeneca/Hong Kong; Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Roche
Research Funding - Eisai; Merck Sharp & Dohme
Travel, Accommodations, Expenses - Ipsen; Novartis
Preliminary results of sequential transarterial chemoembolization and stereotactic body radiotherapy followed by immunotherapy using single tremelimumab regular interval durvalumab in locally advanced, unresectable hepatocellular carcinoma (START-FIT using STRIDE): A single-arm, phase II study.
 
Chi Leung Chiang
Research Funding - AstraZeneca; Merck KGaA; Taiho Pharmaceutical
 
Stephen Lam Chang
No Relationships to Disclose
 
Sik-Kwan Chan
No Relationships to Disclose
 
Ann Shing Lee
No Relationships to Disclose
 
Keith Wan Hang Chiu
No Relationships to Disclose
 
Vanessa Ting Yan Yeung
Employment - Synmosa Biopharma
 
Natalie Sean Man Wong
No Relationships to Disclose
 
Venus Wan Yan Lee
No Relationships to Disclose
 
Vince Wing Hang Lau
No Relationships to Disclose
 
Nancy Kwan Man
No Relationships to Disclose
 
Feng-Ming Spring Kong
Employment - Global Collaborative Oncology Group (GCOG)
Leadership - Global Collaborative Oncology Group
Honoraria - Varian Medical Systems
Speakers' Bureau - AstraZeneca; Merck; Roche; Varian Medical Systems
Research Funding - Varian Medical Systems
Travel, Accommodations, Expenses - Varian Medical Systems
 
Albert Chi Yan Chan
Research Funding - AstraZeneca